Global Medical REIT Inc.
GMRE-PBDrugs in Pipeline
17
Phase 3 Programs
10
Upcoming Catalysts
1
Next Catalyst
Q4 2026
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
fezolinetant
Hot Flashes
33525
Tinea Pedis
Regadenoson
Coronary Artery Disease (CAD)
mirabegron
Neurogenic Detrusor Overactivity
ASP0113
Cytomegalovirus (CMV)-Positive Recipients
Product 55394
Bacterial Vaginosis
pudexacianinium chloride
Intraoperative Ureter Visualization
Roxadustat
Chronic Kidney Disease
gilteritinib
Acute Myeloid Leukemia
Enzalutamide
Advanced Hepatocellular Carcinoma
Test Product 49778
Seborrheic Dermatitis
enfortumab vedotin
Locally Advanced or Metastatic Malignant Solid Tumors
GBT440
Idiopathic Pulmonary Fibrosis
Micafungin
Candidiasis, Systemic
ASP2998
Locally Advanced or Metastatic Malignant Solid Tumors
peficitinib
Arthritis, Rheumatoid
ASP7517
Advanced Malignancies
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
fezolinetant | Phase 3 | Hot Flashes | - | - |
33525 | Phase 3 | Tinea Pedis | - | - |
Regadenoson | Phase 3 | Coronary Artery Disease (CAD) | - | - |
mirabegron | Phase 3 | Neurogenic Detrusor Overactivity | - | - |
ASP0113 | Phase 3 | Cytomegalovirus (CMV)-Positive Recipients | - | - |
Product 55394 | Phase 3 | Bacterial Vaginosis | - | - |
pudexacianinium chloride | Phase 3 | Intraoperative Ureter Visualization | - | - |
Roxadustat | Phase 3 | Chronic Kidney Disease | - | - |
gilteritinib | Phase 3 | Acute Myeloid Leukemia | - | - |
Enzalutamide | Phase 3 | Advanced Hepatocellular Carcinoma | - | - |
Test Product 49778 | Phase 2 | Seborrheic Dermatitis | - | - |
enfortumab vedotin | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors | - | - |
GBT440 | Phase 2 | Idiopathic Pulmonary Fibrosis | - | - |
Micafungin | Phase 2 | Candidiasis, Systemic | - | - |
ASP2998 | Phase 2 | Locally Advanced or Metastatic Malignant Solid Tumors | - | - |
peficitinib | Phase 2 | Arthritis, Rheumatoid | - | - |
ASP7517 | Phase 2 | Advanced Malignancies | - | - |